Skip to Main Content
International Institute for Nanotechnology
Kabiller Prize • News • Events
  • About
    • Message from the Director
    • Partners
      • Centers & Institutes
      • Research Initiatives
      • Laboratories
      • Government Agencies
      • Academic
      • Industrial
    • Facilities
  • People
    • Executive Council
    • Steering Committee
    • Affiliated Faculty
      • Weinberg College of Arts & Sciences
      • Kellogg School of Management
      • Feinberg School of Medicine
      • McCormick School of Engineering & Applied Science
    • Administration
  • Research
    • NanoMedicine
      • Northwestern University Center of Cancer Nanotechnology Excellence (CCNE)
        • NU-CCNE Project 1
        • NU-CCNE Project 2
        • NU-CCNE Project 3
        • NU-CCNE Oligonucleotide Synthesis and Nanoconstructs Core
      • NTU-Northwestern Institute for Nanomedicine (NNIN)
        • NNIN Executive Committee
    • NanoOncology
      • Ronald and JoAnne Willens Center for Nano Oncology
        • Willens Center Project 1
        • Willens Center Project 2
        • Willens Center Project 3
        • Willens Center Project 4
        • Willens Center Project 5
    • NanoEnvironment
      • Nanotechnology for Universal Clean Air & Water Security (NU-CAWS)
        • NU-CAWS Affiliated Faculty
        • NU-CAWS Research Highlights
    • NanoEnergy
    • NanoMaterials
      • Center of Excellence for Advanced Bioprogrammable Nanomaterials (C-ABN)
        • Thrust 1 - Materials & Methods Development
        • Thrust 2 - Functional Substrates
        • Thrust 3 - Advanced Biosensing
    • Molecular Electronics
    • Security & Defense
  • Education
    • Ryan Graduate Fellowships
    • IIN Postdoctoral Fellowships
    • Frontiers in Nanotechnology Seminar Series
    • Research Experience for Undergraduates (REU)
    • All Scout Nano Day
    • Nano Boot Camp for Clinicians
    • Nanotechnology Town Hall Meetings
  • Industry
    • Nanotechnology Corporate Partners (NCP) Program
    • Small Business Partnership
  • Giving
  • Kabiller Prize
    • Overview
    • Nomination Process
    • About David Kabiller
    • Kabiller Prize Winners
      • 2019 Chad Mirkin
      • 2017 Robert Langer
      • 2015 Joe DeSimone
    • Kabiller Young Investigator Award Winners
      • 2019 Molly Stevens
      • 2017 Liangfang Zhang
      • 2015 Warren Chan
  • News
  • Events
    • 2020 IIN Virtual Symposium
    • Frontiers in Nanotechnology Seminar Series
    • Nano Boot Camp for Clinicians
    • Nanotechnology Town Hall Meetings
close
‹ back to news & updates

Cell-free biotechnology could help accelerate COVID-19 therapeutics

Posted by Mark Heiden, Posted in News, Research
Share:

by Amanda Morris

When it comes to fighting a fast-spreading pandemic, speed is critical.

Researchers at Northwestern and Cornell Universities have developed a new platform that could produce new therapies more than 10 times faster than current methods. The secret behind the platform’s unmatched speed is an unlikely tool: bacteria.

After taking the molecular machinery out of bacteria, the researchers then use that machinery to make a product, such as therapeutics, in a safe, inexpensive and rapid manner. The idea is akin to opening the hood of a car and removing the engine, which allows researchers to use the engine for different purposes, free from the constraints of the car.

Through their startup company, SwiftScale Biologics, the Northwestern and Cornell researchers are working to mass produce a promising antibody therapy developed by an outside biotherapeutics company. The antibody binds to the part of the coronavirus that infects the host cells, stopping it in its tracks.

“Everything is moving so incredibly fast, and this is an urgent problem,” said Northwestern’s Michael Jewett. “We believe that cell-free biomanufacturing can cut production times of antiviral medicines to the timescale of just a few months rather than closer to a year. This could help us address the current outbreak.”

Jewett is a professor of chemical and biological engineering in the McCormick School of Engineering and director of Northwestern’s Center for Synthetic Biology. He co-founded SwiftScale Biologics with Matthew DeLisa, the William L. Lewis Professor of Engineering at Cornell and director of the Cornell Institute of Biotechnology, and David Mace from 8VC.

The team had been using the synthetic biology-based platform to mass manufacture potential protein therapeutics for cancer. But it quickly pivoted to leverage the technology to help address the novel coronavirus pandemic, for which no reliable treatment yet exists.

“Since the COVID-19 outbreak, we have dedicated nearly all of our resources to producing an antiviral therapy to fight it,” Jewett said. “Specifically, we are designing simplified antibody-based drugs that can be produced in bacteria rather than mammalian cells, which are far slower and more expensive to scale. In this way, we believe that we will be able to get a COVID-19 treatment into the clinic and ultimately to affected patients worldwide more quickly while increasing access.”

The SwiftScale Biologics team is currently engineering bacterial strains with increased production levels of previously discovered SARS-CoV antibodies as a test case. Next week, the team will test the bacterial strains to produce antibodies for COVID-19. This material will be used for animal studies to confirm the drug’s safety before entering human clinical trials, potentially as soon as this summer.

Jewett is a member of Northwestern’s Chemistry of Life Processes Institute and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and a member of the Steering Committee of the International Institute for Nanotechnology.

Note: Jewett has financial interests in SwiftScale Biologics. Northwestern University has financial interests (equities, royalties) in SwiftScale Biologics.

Read more

No Comments


No comments yet.

Leave a Reply Cancel reply

* Get an image next to your comment by visiting Gravatar.com and uploading a profile photo that links to your email address.

    Categories

    • Awards and Honors
    • Multimedia
    • Nanoscape Newsletter
    • Nanotechnology at Northwestern
    • News
    • Research
    My Tweets

    For Journalists

    NORTHWESTERN MEDIA CONTACT

    Megan Fellman
    Science and Engineering Editor
    Phone: 847-491-3115
    Email: Megan Fellman

    IIN MEDIA CONTACT

    Kathleen Cook
    Chief of Staff
    Phone: 847-467-5335
    Email: Kathleen Cook

Signup For Our Newsletter

Sign up for our newsletter to receive information on events, news, and articles.

More Info
  • Privacy Policy
  • Tech Transfer
  • News & Events
  • Contact Us
  • Sitemap
  • Education
  • About Us
  • Nano101
  • Facilities
  • Partners
Follow Us
  • Facebook
  • Twitter
  • LinkedIn
  • Youtube
  • Instagram

Northwestern University

© International Institute for Nanotechnology